| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.19 | 0.0005 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | -0.094 | 0.003 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.14 | 0.003 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |